# Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers

> **NCT00291473** · PHASE1 · COMPLETED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 9 (estimated)

## Conditions studied

- Esophageal Cancer
- Lung Cancer
- Stomach Cancer
- Breast Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** CHP-HER2, CHP-NY-ESO-1

## Key facts

- **NCT ID:** NCT00291473
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2009-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00291473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00291473, "Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00291473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*